Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85,635 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer.
Lo AA, Johnston J, Li J, Mandikian D, Hristopoulos M, Clark R, Nickles D, Liang WC, Hötzel K, Dunlap D, Pham T, Cai H, Ovacik M, Bravo-Perez D, Mai E, Slaga D, Ellerman D, Ziai J, Totpal K, Lee G, Boswell CA, Payandeh J, Wu Y, Junttila TT. Lo AA, et al. Among authors: wu y. Mol Cancer Ther. 2021 Apr;20(4):716-725. doi: 10.1158/1535-7163.MCT-20-0490. Epub 2021 Feb 3. Mol Cancer Ther. 2021. PMID: 33536191
Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake.
Shang Y, Mao Y, Batson J, Scales SJ, Phillips G, Lackner MR, Totpal K, Williams S, Yang J, Tang Z, Modrusan Z, Tan C, Liang WC, Tsai SP, Vanderbilt A, Kozuka K, Hoeflich K, Tien J, Ross S, Li C, Lee SH, Song A, Wu Y, Stephan JP, Ashkenazi A, Zha J. Shang Y, et al. Among authors: wu y. Mol Cancer Ther. 2008 Sep;7(9):2599-608. doi: 10.1158/1535-7163.MCT-07-2401. Mol Cancer Ther. 2008. PMID: 18790743
CLEC5a-directed bispecific antibody for effective cellular phagocytosis.
Kedage V, Ellerman D, Fei M, Liang WC, Zhang G, Cheng E, Zhang J, Chen Y, Huang H, Lee WP, Wu Y, Yan M. Kedage V, et al. Among authors: wu y. MAbs. 2022 Jan-Dec;14(1):2040083. doi: 10.1080/19420862.2022.2040083. MAbs. 2022. PMID: 35293277 Free PMC article.
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.
Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, Clark R, Fields C, Lewis Phillips GD, Prell RA, Danilenko DM, Franke Y, Stephan JP, Hwang J, Wu Y, Bostrom J, Sliwkowski MX, Fuh G, Eigenbrot C. Schaefer G, et al. Among authors: wu y. Cancer Cell. 2011 Oct 18;20(4):472-86. doi: 10.1016/j.ccr.2011.09.003. Cancer Cell. 2011. PMID: 22014573 Free article.
An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia.
Zheng B, Yu SF, Del Rosario G, Leong SR, Lee GY, Vij R, Chiu C, Liang WC, Wu Y, Chalouni C, Sadowsky J, Clark V, Hendricks A, Poon KA, Chu W, Pillow T, Schutten MM, Flygare J, Polson AG. Zheng B, et al. Among authors: wu y. Clin Cancer Res. 2019 Feb 15;25(4):1358-1368. doi: 10.1158/1078-0432.CCR-18-0333. Epub 2018 Jun 29. Clin Cancer Res. 2019. PMID: 29959143
Harnessing MerTK agonism for targeted therapeutics.
Kedage V, Ellerman D, Chen Y, Liang WC, Borneo J, Wu Y, Yan M. Kedage V, et al. Among authors: wu y. MAbs. 2020 Jan-Dec;12(1):1685832. doi: 10.1080/19420862.2019.1685832. MAbs. 2020. PMID: 31852344 Free PMC article.
85,635 results
You have reached the last available page of results. Please see the User Guide for more information.